Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Phenazopyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.96 |
| ▸ | MEN1 | O00255 | 8/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.96 |
| ▸ | HBB | P68871 | 2/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.96 |
| ▸ | TSHR | P16473 | 2/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.96 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.93 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.93 |
| ▸ | USP2 | O75604 | 1/20 | 0.93 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.93 |
| ▸ | DRD2 | P14416 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenazopyridine SCHEMBL28796595 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL26499 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL29392321 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL19357 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL215655 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL14687482 | 0.98 | MAPT (1.00) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL5973732 | 0.96 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL301672 | 0.96 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL6661856 | 0.96 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 | |
| Phenazopyridine SCHEMBL9151827 | 0.96 | MAPT (0.96) | MAPTMEN1KMT2AMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210356472-A1 | METHODS AND COMPOSITIONS FOR DETECTION AND VISUALIZATION OF OXIDATIVE STRESS-INDUCED CARBONYLATION IN CELLS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2021-11-18 | — | — | US | claimed |
| EP-0586643-B1 | WATCH ASSEMBLY WITH A POWER SOURCE CONSISTING OF A PHOTOVOLTAIC CELL | ASULAB SA (CH) | 1996-11-06 | — | — | EP | claimed |
| EP-0586640-B1 | TRANSPARENT REGENERATIVE PHOTOELECTROCHEMICAL CELL | ASULAB SA (CH) | 1995-09-06 | — | — | EP | claimed |
| US-12565468-B2 | Processes and intermediates for the preparations of Carboprost and Carboprost Tromethamine, and Carboprost Tromethamine prepared therefrom | CHIROGATE INTERNATIONAL INC. (TW) | 2026-03-03 | — | — | US | disclosed |
| WO-2025100466-A1 | COMPLEX FOR TUMOR CHEMODYNAMIC THERAPY | 国立大学法人東海国立大学機構 | 2025-05-15 | — | — | WO | disclosed |
| EP-4509492-A2 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM | Chirogate International Inc. (TW) | 2025-02-19 | — | — | EP | disclosed |
| US-20230131316-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM | CHIROGATE INTERNATIONAL INC. (TW) | 2023-04-27 | — | — | US | disclosed |
| US-20230097470-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM | CHIROGATE INTERNATIONAL INC. (TW) | 2023-03-30 | — | — | US | disclosed |
| EP-4140982-A2 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM | Chirogate International Inc. (TW) | 2023-03-01 | — | — | EP | disclosed |
| US-20210356472-A1 | METHODS AND COMPOSITIONS FOR DETECTION AND VISUALIZATION OF OXIDATIVE STRESS-INDUCED CARBONYLATION IN CELLS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2021-11-18 | — | — | US | disclosed |
| US-10465073-B2 | Organic dye for dye-sensitized solar cell | ENI S.P.A. (IT) | 2019-11-05 | — | — | US | disclosed |
| EP-1507307-A1 | PHOTOELECTRIC CONVERSION DEVICE | Hitachi Maxell, Ltd. (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20040256002-A1 | Organic dye, photoelectric transducing material, semiconductor electrode, and photoelectric transducing device | MITSUBISHI PAPER MILLS LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| US-20040248787-A1 | fusion protein comprising a PTD (protein transduction domain) and an MITF (microphthalmia-associated transcripution factor) variant as an active ingredient with a His tag | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040238826-A1 | Photoelectric conversion device | PANASONIC ELECTRIC WORKS CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1410802-A1 | CELL DEATH INDUCERS FOR MAST CELLS | Mitsubishi Pharma Corporation (JP) | 2004-04-21 | — | — | EP | disclosed |
| US-5681790-A | MIXED OXIDE OXIDATION CATALYST CONTAINING A QUATERNARY AMMONIUM TEMPLATE | SAMSUNG GENERAL CHEMICALS CO., LTD. (KR) | 1997-10-28 | — | — | US | disclosed |
| EP-0083096-B1 | PRODUCTION OF URETHANE COMPOUNDS | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1987-02-25 | — | — | EP | disclosed |
| US-4621149-A | PLATINUM GROUP METAL HALOGEN OR HALOGEN COMPOUND | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1986-11-04 | — | — | US | disclosed |
| EP-0083096-A2 | Production of urethane compounds | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097470-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM | PTGES, PTGES2, PTGIS | MAPT 3267/4885MEN1 4364/4885KMT2A 4479/4885 |
| US-20230131316-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM | PTGES, PTGES2, PTGIS | MAPT 3267/4885MEN1 4364/4885KMT2A 4479/4885 |
| US-12565468-B2 | Processes and intermediates for the preparations of Carboprost and Carboprost Tromethamine, and Carboprost Tromethamine prepared therefrom | PGF, PTGIS, PTGS1 | MAPT 4304/4885MEN1 4136/4885KMT2A 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.